Funding
- Private Investors
- Public FundsRetos-Colaboración - 2017 (RTC-2017-5867-1)- 2019 (RTC-2019-6825-1)CDTI 2017 (IDI-20180106)
- Retos-Desarrollo - 2014 (RTC-2014-2412)- 2016 (RTC-2016-5686)Innpacto 2012 (PT-2012-0561-010000)Torres Quevedo - 2012, 2013, 2014, 2015, 2017, 2018
- AMMIC Project / RIS3CAT 2016-2020
- RD14-1-0114 Desenvolupament MIN-102
- Innovative SME
- ENISA Jóvenes Emprendedores 2012
- TECNIOspring PLUS
Aquest projecte ha rebut finançament del programa de recerca i innovació Horitzó 2020 de la Unió Europea sota l'acord de subvenció Marie Skłodowska-Curie No 712949 (TECNIOspring PLUS), així com de l'Agència per a la Competitivitat de l'Empresa de la Generalitat de Catalunya
- Funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 822968
- NewsSee allMinoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease JournalEuropean Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseasesMinoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and MacauMinoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trialMinoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALDMinoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s AtaxiaMinoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s AtaxiaMinoryx Therapeutics to participate in upcoming investor conferencesMinoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s AtaxiaMinoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
